Optimisation study of alpha-cyclotron production of At-211/Po-211g for high-LET metabolic radiotherapy purposes.
The production of no-carrier-added (NCA) alpha-emitter (211)At/(211g)Po radionuclides for high-LET targeted radiotherapy and immunoradiotherapy, through the (209)Bi(alpha,2n) reaction, together with the required wet radiochemistry and radioanalytical quality controls carried out at LASA is described, through dedicated irradiation experiments at the MC-40 cyclotron of JRC-Ispra. The amount of both the gamma-emitter (210)At and its long half-lived alpha-emitting daughter (210)Po is optimised and minimised by appropriate choice of energy and energy loss of alpha particle beam. The measured excitation functions for production of the main radioisotopic impurity (210)At-->(210)Po are compared with theoretical predictions from model calculations performed at ENEA.
Groppi
F
F
Università degli Studi di Milano and INFN-Milano, LASA, Radiochemistry Laboratory, via F.lli Cervi 201, I-20090 Segrate, Milan, Italy. flavia.groppi@mi.infn.it
Bonardi
M L
ML
Birattari
C
C
Menapace
E
E
Abbas
K
K
Holzwarth
U
U
Alfarano
A
A
Morzenti
S
S
Zona
C
C
Alfassi
Z B
ZB
D001246:Astatine / Q000737:chemistry* / Q000302:isolation & purification; D017357:Cyclotrons; D011059:Polonium / Q000737:chemistry* / Q000302:isolation & purification; D011878:Radiotherapy; D013051:Spectrometry, Gamma
D011059:Polonium; D001246:Astatine